Hossein Borghaei
Impact in
- Oncology top 0.05%
- Cancer Immunotherapy and Biomarkers
- Lung Cancer Research Studies
- CAR-T cell therapy research
- Pulmonary and Respiratory Medicine top 0.1%
- Lung Cancer Treatments and Mutations
- Lung Cancer Diagnosis and Treatment
Papers in
- Oncology 130
- Cancer Immunotherapy and Biomarkers 77
- Lung Cancer Research Studies 38
- CAR-T cell therapy research 12
- Colorectal Cancer Treatments and Studies 8
-
- Lung Cancer Treatments and Mutations 76
- Lung Cancer Diagnosis and Treatment 28
- Co-authors
- Julie Renee Brahmer (23 shared papers)Scott N. Gettinger (17 shared papers)Laura Q.M. Chow (15 shared papers)Scott Joseph Antonia (14 shared papers)Shirish Gadgeel (15 shared papers)Naiyer A. Rizvi (12 shared papers)Joseph Nicholas Bodor (4 shared papers)Frances Alice Shepherd (11 shared papers)
- Journals
- Journal of Thoracic Oncology (26 papers)Annals of Oncology (21 papers)Journal of the National Comprehensive Cancer Network (11 papers)Journal of Clinical Oncology (11 papers)International Journal of Radiation Oncology*Biology*Physics (10 papers)
- Partner nations
- United StatesSpainGermany
In The Last Decade
Hossein Borghaei
198 papers receiving 22.6k citations
Hossein Borghaei's Hit Papers
Peers
Comparison fields: 5 of 130
- Oncology 14.4k
- Pulmonary and Respiratory Medicine 8.3k
- Cancer Research 2.6k
- Immunology 3.4k
- Genetics 562
Countries citing papers authored by Hossein Borghaei
This map shows the geographic impact of Hossein Borghaei's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hossein Borghaei with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hossein Borghaei more than expected).
Fields of papers citing papers by Hossein Borghaei
This network shows the impact of papers produced by Hossein Borghaei. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hossein Borghaei. The network helps show where Hossein Borghaei may publish in the future.
Co-authors
The 25 scholars most cited alongside Hossein Borghaei, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 204 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden Hit paper breakdown → | 2018 | 2504 |
| 2 | Nivolumab plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer Hit paper breakdown → | 2019 | 2191 |
| 3 | First-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung Cancer Hit paper breakdown → | 2017 | 2097 |
| 4 | Sotorasib for Lung Cancers with KRAS p.G12C Mutation Hit paper breakdown → | 2021 | 1325 |
| 5 | Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study Hit paper breakdown → | 2016 | 1199 |
| 6 | Genomic Features of Response to Combination Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer Hit paper breakdown → | 2018 | 851 |
| 7 | Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study Hit paper breakdown → | 2016 | 818 |
| 8 | Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057) Hit paper breakdown → | 2017 | 736 |
| 9 | NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 4.2016 Hit paper breakdown → | 2016 | 622 |
| 10 | Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial Hit paper breakdown → | 2015 | 540 |
| 11 | First-Line Nivolumab Plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer (CheckMate 568): Outcomes by Programmed Death Ligand 1 and Tumor Mutational Burden as Biomarkers Hit paper breakdown → | 2019 | 483 |
| 12 | Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non–Small-Cell Lung Cancer Hit paper breakdown → | 2021 | 477 |
| 13 | Nivolumab Monotherapy for First-Line Treatment of Advanced Non–Small-Cell Lung Cancer Hit paper breakdown → | 2016 | 439 |
| 14 | 2015 | 416 | |
| 15 | 2016 | 386 | |
| 16 | Non–Small Cell Lung Cancer, Version 2.2013 Hit paper breakdown → | 2013 | 382 |
| 17 | Tarlatamab for Patients with Previously Treated Small-Cell Lung Cancer Hit paper breakdown → | 2023 | 345 |
| 18 | 2012 | 308 | |
| 19 | Five-Year Survival Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Metastatic Non–Small-Cell Lung Cancer in CheckMate 227 Hit paper breakdown → | 2022 | 299 |
| 20 | 2019 | 281 |
About Hossein Borghaei
Hossein Borghaei is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Cancer Research, Pathology and Forensic Medicine and Immunology, having authored 204 papers that have together received 23.0k indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (77 papers), Lung Cancer Treatments and Mutations (76 papers), Lung Cancer Research Studies (38 papers), Lung Cancer Diagnosis and Treatment (28 papers), Cancer Genomics and Diagnostics (14 papers), CAR-T cell therapy research (12 papers), Lymphoma Diagnosis and Treatment (12 papers) and Colorectal Cancer Treatments and Studies (8 papers). The work is most often cited by research in Oncology (14.4k citations), Pulmonary and Respiratory Medicine (8.3k citations), Cancer Research (2.6k citations), Immunology (3.4k citations) and Genetics (562 citations). Hossein Borghaei has collaborated with scholars based in United States, Spain and Germany. Frequent co-authors include Julie Renee Brahmer, Scott N. Gettinger, Laura Q.M. Chow, Scott Joseph Antonia, Shirish Gadgeel, Naiyer A. Rizvi, Joseph Nicholas Bodor, Frances Alice Shepherd, Rosalyn Anne Juergens and Matthew David Hellmann. Their work appears in journals such as Journal of Thoracic Oncology, Annals of Oncology, Journal of the National Comprehensive Cancer Network, Journal of Clinical Oncology and International Journal of Radiation Oncology*Biology*Physics.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.